Bictegravir

So topic three is Another approval that was on August 28th, this is the FDA's approval of Bixlenvo from Gilead.

This is Bictegravir 75 milligrams plus Lenacapavir 50 milligrams in a once daily single tablet.

So it pairs the integrase inhibitor from Bictarvy with Lenacapavir, which is a first-in-class capsid inhibitor with no cross-resistance to other antiretroviral classes.

So this is indicated as a switch option for adults who are already urologically suppressed.

I'm sure many of you may be asking, geez, where's the data for BicLen and the new guideline update? Well, the BicLen was just recently approved, and it does not include that.

So they do mention this, so that this is the Bictegravir with Lanocapavir combination pill.

based on some of the Artistry 1 and Artistry 2 data.

But at the time of this guideline release, they specifically mentioned that this is going to be addressed in a future update to the guidelines.